This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The study took the form of an unblended, randomised, controlled, multi-centre trial. The patients were randomly assigned to one of the 15 treatment groups. More specifically, 643 patients were assigned to the various rosuvastatin groups, 641 patients to the atorvastatin groups, 655 patients to the simvastatin groups and 492 patients to the pravastatin groups. The patients were followed up for 6 weeks and 2,288 patients (94.1%) completed the trial.
Analysis of effectiveness
It was not reported whether the analysis was conducted on an intention to treat basis or otherwise. The primary health outcomes were percentage reductions in LDL and achievement of goals set by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). Baseline measurements showed that 29% of the patients met the NCEP ATP III LDL goal. The mean LDL levels ranged from 187 mg/dL for patients assigned to rosuvastatin 20 mg, pravastatin 29 mg and simvastatin 40 mg, to 194 mg/dL for the rosuvastatin 40-mg group. "Other" baseline characteristics were reported to be similar among the treatment groups.
Effectiveness results
Pair-wise dose-to-dose comparisons of efficacy were presented, as well as the percentage reductions in LDL level and the percentage of patients achieving NCEP ATP III targets after 6 weeks used in the economic evaluation.
Rosuvastatin 10 mg achieved a 45.8% reduction in LDL compared with: atorvastatin 10 mg, which achieved a 3.6.8% reduction; pravastatin 10 mg, which achieved a 20.1% reduction; pravastatin 20 mg, which achieved a 24.4% reduction; pravastatin 40 mg, which achieved a 29.7% reduction; simvastatin 10 mg, which achieved a 28.3% reduction; simvastatin 20 mg, which achieved a 35% reduction; and simvastatin 40 mg, which achieved a 38.8% reduction, (p<0.001).
The results for pair-wise comparisons of rosuvastatin 20 mg were also presented in the paper.
Rosuvastatin 40 mg achieved a 55.0% reduction in LDL compared with: atorvastatin 40 mg, which achieved a 47.8% reduction; pravastatin 40 mg, which achieved a 29.8% reduction; simvastatin 40 mg, which achieved a 38.8% reduction; and simvastatin 80 mg, which achieved a 45.8% reduction, (p<0.001).
However, the difference between rosuvastatin 40 mg and atorvastatin 80 mg, which showed a reduction of 51.1%, was not significant.
Clinical conclusions
Overall, rosuvastatin reduced LDL levels significantly more than simvastatin and pravastatin in all 14 pair-wise comparisons in the STELLAR trial, (p<0.001). Rosuvastatin may also be more efficacious in meeting NCEP ATP III goals than atorvastatin, simvastatin and pravastatin.
Measure of benefits used in the economic analysis
The measures of benefit used in the economic analysis were the percentage reductions in LDL and the percentage of patients achieving NCEP ATP III targets.
Direct costs
The only costs included in the study were the direct costs of the drugs used. The time periods considered were limited to 12 months, obviating the need for discounting. The quantities used were reported as daily doses. The cost per dose was reported separately. The costs were based on "average wholesale prices" using the Drug Topics Red Book. The timeline for costs was May 2004.
Statistical analysis of costs
The costs were treated deterministically.
Indirect Costs
In line with the perspective adopted, the study did not report the indirect costs.
Currency

US dollars ($).
Sensitivity analysis
No sensitivity analysis was reported
Estimated benefits used in the economic analysis
The reductions in LDL level after 6 weeks of treatment were as follows: 
Cost results
The estimated daily costs for the various drug regimens were as follows: No confidence intervals or other statistical tests were reported for the costs which used average US wholesale prices.
Synthesis of costs and benefits
The costs and benefits were combined in cost-effectiveness ratios in which the incremental costs of all regimens were reported in comparison with the baseline measurements.
Rosuvastatin 40 mg dominated all other treatment options with the exception of atorvastatin 10 mg.
An incremental analysis with respect to dominated treatments would be superfluous. It might have been performed with respect to the slightly cheaper atorvastatin 10 mg, but was not.
The annual drug cost per percentage reduction in LDL was reported to be $25.63 for atorvastatin 10 mg and, respectively, $20.92, $18.28 and $17.42 for the 10-, 20-and 40-mg formulations of rosuvastatin.
The findings were confirmed when the outcomes were measured as achievement of NCEP ATP III recommendations. Rosuvastatin was the most effective, with 82.2% of patients achieving the recommendations. This was substantially higher than the slightly cheaper atorvastatin, where 69% of the patients achieved the recommendations.
Neither a sensitivity analysis nor statistical tests were performed on the cost-effectiveness ratios.
Authors' conclusions
Rosuvastatin was the most cost-effective treatment in terms of the percentage reduction in low-density lipoprotein (LDL) when compared with other statins, with the 40-mg formulation being the most cost-effective.
CRD COMMENTARY -Selection of comparators
The study compared 14 treatment regimens involving differing strengths of four drugs. Rosuvastatin was reported as being a recently approved potent statin. The other three drugs were justified as drugs that were "available". The effect of each treatment option was compared with a "baseline" in which patients were reported to be receiving 'both primary and secondary prevention, according to NCEP ATP III guidelines and with or without coronary heart disease and coronary heart disease risk equivalents". Thus, the treatments were compared both with pre-existing treatments and with each other in terms of improvements over pre-existing treatments. In such a large multi-centre national trial, it might be reasonable to suppose that the pre-existing treatments were representative of practice within the country (the USA). You are advised to consider whether the same practice applies in your own setting.
Validity of estimate of measure of effectiveness
The study was based on a multi-centre randomised design, which was appropriate to the study question and for which the study sample appears to have been representative. There was a small difference between groups in their LDL level at baseline, with patients receiving rosuvastatin 40 mg having a mean score of 194 mg/dL compared with 187 mg/dL (the lowest LDL) for patients receiving rosuvastatin 20 mg, pravastatin 20 mg and simvastatin 40 mg. If the percentage reductions in LDL were to differ with different initial levels of LDL, then this might have introduced a small bias into the results. No attempt appears to have been made to control for such an eventuality. Other patient characteristics were
